Alkaline phosphatase formulations
US-12048735-B2 · Jul 30, 2024 · US
US9770474B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9770474-B2 |
| Application number | US-17510808-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 17, 2008 |
| Priority date | Jul 17, 2007 |
| Publication date | Sep 26, 2017 |
| Grant date | Sep 26, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Red blotches on the skin such as those associated with environmental stresses, or red blotches associated with a skin disorder, for example those occurring during rosacea, are treated/reduced by administering to individuals afflicted therewith, thus effective amounts of at least one extract of a non-photosynthetic and non-fruiting filamentous bacterium cultured in a medium which includes at least one non-sulfurous mineral and/or thermal water, e.g., an extract derived from the bacterium Vitreoscilla filiformis , in particular the strain ATCC 15551, cultured in a medium enriched with water from La Roche Posay.
Opening claim text (preview).
What is claimed is: 1. A method of treating erythema in a human suffering from atopic dermatitis and/or erythema in a human suffering from seborrheic dermatitis, the method comprising administering an effective amount of an extract of Vitreoscilla filiformis to the human in need thereof to treat the erythema in a human suffering from atopic dermatitis and/or the erythema in a human suffering from seborrheic dermatitis, wherein the Vitreoscilla filiformis is cultured in a medium which comprises at least one non-sulfurous mineral and/or thermal water. 2. The method of claim 1 , wherein said thermal water is from La Roche Posay. 3. The method of claim 1 , wherein said at least one non-sulfurous mineral and/or thermal water has a total mineral content ranging from 400 to 900 mg/l. 4. The method of claim 1 , wherein said at least one non-sulfurous mineral and/or thermal water has a total concentration of carbonates and of bicarbonates of at least 150 mg/l and a concentration of silicon oxide of at least 6 mg/l. 5. The method of claim 1 , wherein said thermal water is from Vittel, from the Vichy basin, from Uriage, from La Bourboule, from Enghien-les-Bains, from Saint-Gervais-les-Bains, from Néris-les-Bains, from Allevard-les-Bains, from Digne, from Maizières, water from Neyrac-les-Bains, from Lons-le-Saunier, from Eaux-Bonnes, from Rochefort, from Saint Christau, from Les Fumades or from Tercis-les-Bains. 6. The method of claim 3 , wherein said at least one non-sulfurous mineral and/or thermal water has a concentration of calcium ions of at least 100 mg/l. 7. The method of claim 1 , said Vitreoscilla filiformis extract is from 0.001 to 20% by weight of the total weight of a composition comprised thereof. 8. The method of claim 1 , further comprising administering to said human at least one agent selected from the group consisting of retinoids, corticosteroids, free-radical scavengers, alpha-hydroxy, alpha-keto acids, ion channel blockers, wetting agents, depigmenting agents, emollients, moisturizers, anti-seborrheic, anti-acne agents, antibiotics, anti-fungal agents, agents for promoting hair regrowth, non-steroidal anti-inflammatories, carotenoids, anti-psoriatic agents, preservatives, stabilizers, moisture regulators, emulsifiers, ultraviolet A screens, ultraviolet B screens, and antioxidants. 9. The method of claim 1 , further comprising administering to said human at least one agent selected from the group consisting of vasoprotector agents that act on the microcirculation, vasoconstrictor agents that act on the microcirculation, a substance that gives the skin a color, and an active agent for treating rosacea. 10. The method of claim 9 , further comprising administering to said human a green colorant. 11. The method of claim 1 , wherein the culture medium consists essentially of water from La Roche Posay, autolyzed yeast extract, plant peptone, anhydrous glucose, Heller microelements and calcium chloride.
Antiseborrheics · CPC title
Drugs for dermatological disorders · CPC title
Mineral waters; Sea water · CPC title
Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title
Preparations containing skin colorants, e.g. pigments (preparations in powder form A61Q1/12) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.